ArcherDX, Inc. Announces Close of $60M Financing to Advance Companion Diagnostic and Minimal Residual Disease Monitoring Product Portfolio BOULDER, Colo., May, 15, 2019 /PRNEWSWIRE/– ArcherDX, […]

ArcherDX, Inc. Announces Close of $60M Financing to Advance Companion Diagnostic and Minimal Residual Disease Monitoring Product Portfolio BOULDER, Colo., May, 15, 2019 /PRNEWSWIRE/– ArcherDX, […]

ArcherDX, Inc. Announces the Appointment of Steven J. Kafka, Ph.D. as Executive Chairman of the Board of Directors BOULDER, Colo., May, 29, 2019 /PRNEWSWIRE/– ArcherDX, […]

ArcherDX announces collaboration with University College London to Investigate the Novel Use of Cell-Free Circulating Tumor DNA to Detect Disease Recurrence in Lung Cancer Patients […]

ArcherDX, Inc. Announces Expansion of Executive Leadership Team as Company Continues to Experience Rapid Growth BOULDER, Colo., March 5, 2019 — ArcherDX, Inc., a molecular […]

ArcherDX, Inc. Announces Broad-Based Strategic Collaboration with Genosity February 12, 2019 BOULDER, CO-ArcherDX, Inc., a molecular technology company dedicated to developing breakthrough solutions that advance […]

ArcherDX, Inc. Acquires Baby Genes, a Genetics-Based Personalized Medicine Company January 30, 2019 BOULDER, CO-ArcherDX, Inc., a molecular technology company dedicated to developing breakthrough solutions […]

ArcherDX and Illumina Partner for Future to Co-Market Portfolio of Planned In-Vitro Diagnostic (IVD) Tests Co-marketing partnership to drive awareness of ArcherDX IVD products and […]